StridesStrides Acrolabs, which struck a drug supply deal with Pfizer on Wednesday, said it is discussing similar drug supply deal for niche therapeutics areas with global drug pharma companies. The Bangalore-based company will start getting part of the money from its deal with Pfizer this quarter onwards and that such deals would drive its future growth, a senior company executive said.

Arun Kumar, founder and managing director at Strides Acrolabs told pharmaquest.biz, “We continue to get interests for other niche injectables segments such as peptides, hormones and penams. We will keep collaborating with partners as part of our strategy.” On Wednesday, it had entered into a drug supply deal with Pfizer allowing the American company’s generic arm to market 40 of its medicines, mostly cancer injectables, in the US market.

Mr Kumar added the company would start getting license fee from this quarter onwards. The first product under the collaboration is expected to be launched this year and additional revenue would flow in when the products are launched. The company is also exploring possibilities of expanding the collaboration to other markets as well, he added.

About 30% of the company’s annual sales last year (about Rs 1,300 crore) came from the injectable business. But company is betting heavily on this segment and about 90% of its research and development expenses are on injectables, he added. It has filed over 100 products for regulatory approval across geographies.

Global pharma majors such as Pfizer and GlaxoSmithKline are partnering Indian companies to scale up their generic business as they face dwindling sales.